CLINICAL TRIALS PROFILE FOR GERMA-MEDICA MG

All Clinical Trials for GERMA-MEDICA MG

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00270829 ↗	Renal Effects of Intrarenal Nesiritide	Terminated	University of Maryland	Phase 4	2005-12-01	The impact of nesiritide in CHF is unclear, but it is possible that systemic vasodilation leads to adverse consequences even if the direct renal effects are positive. Therefore, this study will look at the effects of direct intrarenal administration of nesiritide on GFR and RPF.
NCT00270829 ↗	Renal Effects of Intrarenal Nesiritide	Terminated	University of Maryland, Baltimore	Phase 4	2005-12-01	The impact of nesiritide in CHF is unclear, but it is possible that systemic vasodilation leads to adverse consequences even if the direct renal effects are positive. Therefore, this study will look at the effects of direct intrarenal administration of nesiritide on GFR and RPF.
NCT01033630 ↗	Cardiovascular-Protective Effects of Herbal Medicine Danshen-Gegen	Completed	Chinese University of Hong Kong	Phase 2	2006-01-01	Atherosclerosis (in particular stroke and heart attack) is the most important health issue in modernized society and high blood pressure is an important predisposing factor. Hypertensive subjects with other chronic disease such as diabetes mellitus or impaired renal function are particularly vulnerable to these atherosclerotic complications in spite of standard antihypertensive therapies. Danshen and Gegen are commonly used in Chinese materia medica as treatment for cardiac symptoms and atherosclerosis-related disorders. The objective of this study is to test Danshen and Gegen as an cardiovascular-protective adjunctive regimen to prevent high-risk hypertensive cohort from primary atherosclerosis.
NCT01677247 ↗	Bioequivalence Study of 4 mg Glimepiride Tablet	Completed	Dexa Medica Group	N/A	2011-02-01	This was a randomized, single blind, two-period, two sequence cross-over study under fasting condition to compare the bioavailability of two glimepiride 4 mg tablet formulations (test and reference formulations).
NCT01682577 ↗	Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition	Completed	Dexa Medica Group	N/A	2008-09-01	The objective of this study was to find out whether the bioavailability of PT Dexa Medica's formulation of 4 mg perindopril tert-butylamine tablets was equivalent to that of the innovator's product (Prexum® 4 mg, Servier).

Clinical Trial Conditions for GERMA-MEDICA MG

Condition Name

Condition Name for GERMA-MEDICA MG
Intervention	Trials
Healthy	7
Small-cell Lung Cancer	2
Palliative Care	1
Diabetes Mellitus	1

Condition MeSH

Condition MeSH for GERMA-MEDICA MG
Intervention	Trials
Lung Neoplasms	2
Small Cell Lung Carcinoma	2
Tuberculosis, Pulmonary	1
Diabetic Neuropathies	1

Clinical Trial Locations for GERMA-MEDICA MG

Trials by Country

Trials by Country for GERMA-MEDICA MG
Location	Trials
China	11
Indonesia	8
Colombia	4
Panama	1
Austria	1

Trials by US State

Trials by US State for GERMA-MEDICA MG
Location	Trials
Maryland	1

Clinical Trial Progress for GERMA-MEDICA MG

Clinical Trial Phase

Clinical Trial Phase for GERMA-MEDICA MG
Clinical Trial Phase	Trials
Phase 4	3
Phase 2/Phase 3	3
Phase 2	7

Clinical Trial Status

Clinical Trial Status for GERMA-MEDICA MG
Clinical Trial Phase	Trials
Completed	11
Recruiting	6
Unknown status	4

Clinical Trial Sponsors for GERMA-MEDICA MG

Sponsor Name

Sponsor Name for GERMA-MEDICA MG
Sponsor	Trials
Dexa Medica Group	8
Chinese University of Hong Kong	2
Peking University First Hospital	2

Sponsor Type

Sponsor Type for GERMA-MEDICA MG
Sponsor	Trials
Other	44
Industry	11